Insulin Resistance & ADHD — USA & UK 1975–2022

Insulin Resistance & ADHD

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Insulin resistance estimated from HOMA-IR survey data and proxy metabolic markers. ADHD prevalence from national health surveys. Note: ADHD data pre-1990 is limited; earlier estimates are back-projections from clinical records and prescription data.

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but many other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

United States

USA — Insulin Resistance vs ADHD

1975 – 2022  |  % of population
Insulin Resistance
ADHD Diagnosed
United Kingdom

UK — Insulin Resistance vs ADHD

1975 – 2022  |  % of population
Insulin Resistance
ADHD Diagnosed
r = 0.94
USA
IR ↔ ADHD
r = 0.91
UK
IR ↔ ADHD
+620%
USA ADHD rise
1990 – 2022
+850%
UK ADHD rise
2000 – 2022
Important methodological note: ADHD diagnosis rates are significantly influenced by evolving diagnostic criteria (DSM-III 1980 → DSM-IV 1994 → DSM-5 2013), growing clinical awareness, and improved access to assessment services — particularly in the UK where ADHD services were historically under-resourced. These factors independently drive measured prevalence upward. The correlation with insulin resistance does not imply causation. However, emerging research does link metabolic dysfunction and neuroinflammation to neurodevelopmental conditions, and the parallel rise across both countries warrants serious scientific attention.
Data sources
ADHD USA: CDC/NHIS national surveys 1997–2022 (children 4–17); prevalence rose from 6.1% (1997) to 10.5% (2022). Adult ADHD: NSDUH/SAMHSA 2003–2022 (~4–5%). Pre-1997 back-projections from DEA prescription stimulant data and clinical studies.
https://www.cdc.gov/adhd/data/adhd-throughout-the-years.html
https://pmc.ncbi.nlm.nih.gov/articles/PMC10551769/
ADHD UK: IQVIA Medical Research Data primary care database 2000–2018 (Riglin et al., BJPsych 2023); NHS Digital ADHD prescription trends 2000–2022. Pre-2000 estimates from British child psychiatry records.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10375867/
https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community
Insulin Resistance USA: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); Frontiers meta-analysis 2025. Pre-1988 proxy estimates from obesity and fasting glucose trends.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12411212/
Insulin Resistance UK: NHS Health Survey England 2003–2021; GBD 2019 metabolic risk data; Diabetes UK epidemiology reports 1990–2022.
https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
Scroll to Top
MENU
For Radiant Health